ArticleAnnals of neurology2021
NIA-AA Alzheimer's Disease Framework: Clinical Characterization of Stages.
Article in Annals of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05153941 (DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders), which is not on this map. Cited by 43 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DNS Cohort Study Aimed at Understanding the Pathophysiology of AD and AD Related Disorders (ADRD)
Who cites it
43 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Machine learning applications in vascular neuroimaging for the diagnosis and prognosis of cognitive impairment and dementia: a systematic review and meta-analysis.Alzheimer's research & therapy · 2025Pooled it
- Curcumin and Dementia: A Systematic Review of Its Effects on Oxidative Stress and Cognitive Outcomes in Animal Models.International journal of molecular sciences · 2025Pooled it
- The application of saccades to assess cognitive impairment among older adults: a systematic review and meta-analysis.Aging clinical and experimental research · 2023Pooled it
- Machine-Based Learning Shifting to Prediction Model of Deteriorative MCI Due to Alzheimer's Disease - A Two-Year Follow-Up Investigation.Current Alzheimer research · 2022Trial
- Modelling the temporal evolution of plasma p-tau217, amyloid PET, tau PET and cognition.Brain : a journal of neurology · 2026Article
- Distinct Filament Conformation for Receptor-Bound Amyloid-β from Alzheimer's Disease Brain.Nature communications · 2026Article
- Combining p-tau217 and digital cognitive testing to predict cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Cognitive-behavioral phenotypes inFrontiers in molecular neuroscience · 2026Article
- Clinical value of dyslipidemia and glycemic variability for progression to dementia in type 2 diabetes mellitus-associated mild cognitive impairment.Neurogenetics · 2025Article
- Distinct Filament Conformation for Receptor-Bound Amyloid-ß from Alzheimer's Disease Brain.bioRxiv : the preprint server for biology · 2025Article
- Article
- Neuropsychiatric symptoms and progression to pathologically confirmed Alzheimer's disease.Brain : a journal of neurology · 2025Article
- Using memory recall response time on digital cognitive testing to detect subtle cognitive changes among cognitively unimpaired older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Clinical and MRI Correlates of β-Amyloid Load Inconsistent With Its Presumed Neurotoxicity in Cognitively Healthy Ageing.Journal of neurochemistry · 2025Article
- Subjective Cognitive Impairment (SCI) and Future Dementia Risk in the National Health and Aging Trends Study (NHATS) During 2012-2019.Journal of aging and health · 2025Article
- Auto-branch multi-task learning for simultaneous prediction of multiple correlated traits associated with Alzheimer's disease.Frontiers in genetics · 2025Article
- Association of precuneus Aβ burden with default mode network function.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- EEG-based graph network analysis in relation to regional tau in asymptomatic Alzheimer's disease.Brain communications · 2025Article
- Rethinking neuropsychological test validity in dementia assessment: a critical review in the age of neuroimaging and digital markers.Frontiers in human neuroscience · 2025Review
- Different Grey Matter Microstructural Patterns in Cognitively Healthy Versus Typical Ageing Healthy Versus Typical Brain Ageing.NMR in biomedicine · 2025Article
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
backgroundTo operationalize the National Institute on Aging - Alzheimer's Association (NIA-AA) Research Framework for Alzheimer's Disease 6-stage continuum of clinical progression for persons with abnormal amyloid.
methodsThe Mayo Clinic Study of Aging is a population-based longitudinal study of aging and cognitive impairment in Olmsted County, Minnesota. We evaluated persons without dementia having 3 consecutive clinical visits. Measures for cross-sectional categories included objective cognitive impairment (OBJ) and function (FXN). Measures for change included subjective cognitive impairment (SCD), objective cognitive change (ΔOBJ), and new onset of neurobehavioral symptoms (ΔNBS). We calculated frequencies of the stages using different cutoff points and assessed stability of the stages over 15 months.
resultsAmong 243 abnormal amyloid participants, the frequencies of the stages varied with age: 66 to 90% were classified as stage 1 at age 50 but at age 80, 24 to 36% were stage 1, 32 to 47% were stage 2, 18 to 27% were stage 3, 1 to 3% were stage 4 to 6, and 3 to 9% were indeterminate. Most stage 2 participants were classified as stage 2 because of abnormal ΔOBJ only (44-59%), whereas 11 to 21% had SCD only, and 9 to 13% had ΔNBS only. Short-term stability varied by stage and OBJ cutoff points but the most notable changes were seen in stage 2 with 38 to 63% remaining stable, 4 to 13% worsening, and 24 to 41% improving (moving to stage 1).
interpretationThe frequency of the stages varied by age and the precise membership fluctuated by the parameters used to define the stages. The staging framework may require revisions before it can be adopted for clinical trials. ANN NEUROL 2021;89:1145-1156.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.